Results 31 to 40 of about 7,425,086 (301)
Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]
, 2003 Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Kolb, Hans-Jochem +8 more
core +1 more source
Treatments and supportive therapies for oral manifestations of chronic graft-versus-host disease
Acta Scientiarum. Health Sciences, 2016 The aim of this study was to conduct a systematic review of treatments and therapies for oral manifestations of chronic graft-versus-host disease, aiming at improving patients’ quality of life and mainly the reduction of mortality caused by graft-versus-
Rafaella Gabriel Maiolino +5 more
doaj +1 more source
Haematologica, 2015 Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance.
Joseph Pidala +15 more
doaj +1 more source
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study [PDF]
, 2020 Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids.
López Corral, Lucía +8 more
core +6 more sources
Hematology, Transfusion and Cell Therapy, 2018 Background: Hematopoietic stem cell transplantation is a curative treatment for many patients with hematological disorders. Donor–recipient genetic disparity, especially involving the human leukocyte antigen system is a critical factor for transplant ...
Alessandra Paz +12 more
doaj +1 more source
Frontiers in Immunology, 2020 Graft-versus-host disease (GvHD) remains the second leading cause of death in allogeneic hematopoietic stem cell transplantation recipients, highlighting the need for improved preventative strategies.
Megan S. Molina +14 more
doaj +1 more source
Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease [PDF]
, 2010 Background Multipotent mesenchymal stromal cells suppress T-cell function in vitro, a property that has underpinned their use in treating clinical steroid-refractory graft-versus-host disease after allogeneic hematopoietic stem cell transplantation ...
K. Atkinson +19 more
core +1 more source
Frontiers in Oncology, 2021 Acute Myeloid Leukemia (AML) is the commonest indication for allogeneic stem cell transplantation (allo-SCT) worldwide. The increasingly important role of allo-SCT in the management of AML has been underpinned by two important advances.
Justin Loke +5 more
doaj +1 more source
Human Graft Versus Host Disease [PDF]
, 1980 Human graft versus host disease is composed of 2 distinct clinical entities, acute graft versus host disease and chronic graft versus host disease, which have different pathogenesis.
Robertson Parkman +5 more
core +1 more source
International Journal of Medical Students, 2023 BACKGROUND: Graft-versus-host disease (GVHD) continues to compromise the overall success of allogenic hematopoietic stem cell transplantation. It is the most important cause of morbidity and non-relapse mortality after allogeneic hematopoietic stem cell
Fernando Tienda-López +4 more
doaj +1 more source